Randomized, Double Blind, Placebo Controlled "First-in-human" Study to Assess the Safety and Tolerability of Single Ascending Oral Doses and Multiple Oral Doses of MBF-015 in Healthy Young Volunteers
Latest Information Update: 26 Sep 2023
At a glance
- Drugs MBF 015 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; First in man
- Sponsors Medibiofarma
- 26 Sep 2023 New trial record